Zacks Investment Research has recently initiated coverage of NeurAxis, Inc. (NRXS) , assigning a "Neutral" recommendation to the company's shares. This assessment comes amid a mixed outlook for the company, which has been making notable strides in the neuromodulation therapies space despite industry challenges.NRXS, headquartered in Carmel, IN, specializes in developing neuromodulation therapies to address chronic conditions, particularly in pediatric populations. NeurAxis' flagship product, the IB-Stim, is ...